Key Takeaways
- On March 31, 2026, ARK Invest allocated approximately $240 million to OpenAI Group shares distributed among three exchange-traded funds
- The investment coincided with OpenAI’s record-breaking $122 billion capital raise, establishing an $852 billion company valuation
- Additional ARK purchases included stakes in CoreWeave and DoorDash, expanding positions in both firms
- ARK divested more than 600,000 Strata Critical Medical shares while reducing holdings in Veracyte and Teradyne
- This strategic move provides everyday ETF investors with unprecedented indirect exposure to a pre-IPO private enterprise through ARK’s publicly available funds
Cathie Wood’s investment firm executed one of its most significant single-session transactions on March 31, 2026, securing approximately $240 million in OpenAI Group equity distributed across three exchange-traded funds.
BREAKING: Cathie Wood is adding OpenAI to $ARKK, $ARKF, and $ARKW
Each fund will hold a roughly 3% stake, giving retail investors direct exposure to one of the most sought-after private companies in the world pic.twitter.com/7ytR0e9uNz
— Ark Invest Tracker (@ArkkDaily) March 31, 2026
The allocation was distributed among the ARK Innovation ETF, ARK Next Generation Internet ETF, and ARK Blockchain and Fintech Innovation ETF. Following this transaction, each fund maintains approximately a 3% ownership stake in OpenAI Group PBC, Series C.
Prior to this strategic deployment, only ARK’s closed-end Venture Fund maintained OpenAI equity positions. That fund initially established its position in 2024, subsequently increasing exposure with a $250 million commitment in October of the same year.
The strategic timing of ARK’s acquisition aligns perfectly with a significant capital announcement from OpenAI. That same day, OpenAI finalized its most substantial funding round to date, securing $122 billion and elevating its enterprise valuation to $852 billion.
According to OpenAI, the substantial capital infusion will fund semiconductor acquisitions, data center infrastructure expansion, and talent recruitment. Additionally, the organization facilitated approximately $3 billion in direct share sales to individual investors through a private placement coordinated by three leading financial institutions.
OpenAI CFO Sarah Friar stated the organization aims to provide retail investors access not only to its technological innovations but also to the financial returns associated with its growth trajectory.
Implications of OpenAI ETF Integration for Everyday Investors
By incorporating OpenAI equity into publicly available ETFs, ARK has established a pathway for mainstream investors to gain exposure to a privately held enterprise. This represents an uncommon opportunity, as most individual investors lack access to pre-IPO equity positions.
However, there are considerations. While ETFs maintain continuous trading throughout market hours, private company shares lack real-time price discovery. Portfolio managers depend on valuation estimates for these holdings and may need to liquidate more liquid securities to accommodate shareholder redemptions.
Cathie Wood addressed the transaction, noting that within the fintech landscape, agentic artificial intelligence will generate remarkable investment opportunities.
Additional ARK Portfolio Activity on March 31
Beyond the OpenAI acquisition, ARK secured 26,515 shares of CoreWeave, a cloud infrastructure provider, representing approximately $2.05 million. CoreWeave stock appreciated 12% during that trading session.
ARK similarly acquired 14,729 DoorDash shares valued at $2.21 million. This purchase followed a previous DoorDash acquisition one day earlier, expanding ARK’s exposure to the on-demand food delivery industry.
Regarding portfolio reductions, ARK liquidated 612,483 Strata Critical Medical shares for $2.56 million. The healthcare services company specializes in urgent logistics and medical support for healthcare facilities throughout the United States.
ARK additionally divested 6,204 Teradyne shares worth $1.84 million and 115,718 Veracyte shares across both ARKK and ARKG ETFs, representing a combined $3.52 million. The firm had been systematically reducing its Veracyte exposure throughout the preceding week.
OpenAI’s landmark funding round concluded with an $852 billion valuation on March 31, 2026, precisely when ARK deployed its $240 million investment across three primary ETFs.
